沙利度胺联合CAPIRI方案治疗晚期结直肠癌的临床研究

Clinical Study of CAPIRI plus thalidomide in the treatment of advanced colorectal cancer

目的:观察沙利度胺联合希罗达和伊立替康(CAPIRI方案)治疗晚期结直肠癌的临床疗效和不良反应。方法:沙利度胺200mg,睡前顿服,d1-14;伊立替康150mg/m2,静脉滴注90min,d1;希罗达1000mg/m2,每日2次,连服14天;每3周重复,2周期后评定疗效。结果:全组12例均可评价疗效,其中完全缓解(CR)0例,部分缓解(PR)6例(50%),稳定(SD)4例(33.33%),病情进展(PD)2例(16.67%),总有效率(ORR)50%,疾病控制率(DCR)83.33%。主要不良反应为腹泻7例(58.33%),中性粒细胞减少5例(41.67%),恶心呕吐4例(33.33%)。结论:该方案治疗晚期结直肠癌有效率高,不良反应能耐受。

Objective：To observe the therapeutic effects and adverse effect of Thalidomide combined with xeloda and irinotecan（CAPIRI） in treatment of advanced colorectal cancers.Methods： Thalidomide（200mg/d,d1-14）,irinotecan 150mg/m2,90 minutes iv on day 1;xeloda 1000mg/m2,administered twice daily from day 1 to 14;three weeks as one circle.Efficacy was evaluated after 2 circles.Results： All 12 patients with advanced colorectal cancers received,treatment no case achieved complete response（CR）,6 patients partial response（PR）（50%）,4 patients stable disease（SD）（33.33%）,2 patients progression disease（PD）（16.67%）.Overall response rate was 50%,disease control rate（DCR）was 83.33%.The major toxicity was diarrhea（58.33%）,leucopenia（41.67%）,nausea,vomiting（33.33%）.Conclusion： The regimen of thalidomide combined CAPIRI is effective and toxicity is reduced clearly in advanced colorectal cancer.